Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: Gazelle end of induction analysis

Citació

  • Canales MA, Buchholz TA, Bortolini JAP, Fogliatto LM, Ishikawa T, Izutsu K, Salar A, Sharman JP, Klingbiel D, Pokala S, Vorozheikina E, Trask P, Parreira J, Hübel K. Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: Gazelle end of induction analysis. Hemasphere. 2023 Mar 30;7(4):e860. DOI: 10.1097/HS9.0000000000000860

Enllaç permanent

Descripció